Evidence map›Paper›PMID 27163757›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016

Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection.

C M Lin, R J Plenter, M Coulombe, R G Gill

Open access · hybridAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article
  4. NK Cells: Not Just Followers But Also Initiators of Chronic Vascular Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  5. Review
  6. Article
  7. CD1d-independent NK1.1Frontiers in immunology · 2022
    Article
  8. The natural killer cell activating receptor, NKG2D, is critical to antibody-dependent chronic rejection in heart transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Article
  9. Therapies for Chronic Allograft Rejection.Frontiers in pharmacology · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Immune Reconstitution Disorders: Spotlight on Interferons.International journal of biomedical investigation · 2019
    Article
  16. Evaluation of serum interferons in patients with age-related macular degeneration.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019
    Article
  17. Deletion of the activating NK cell receptor NKG2D accelerates rejection of cardiac allografts.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Article
  18. Review
  19. Article
  20. Recent advances in allograft vasculopathy.Current opinion in organ transplantation · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

C M LinDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Aurora, CO. christine.lin@ucdenver.edu.
R J PlenterDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Aurora, CO.
M CoulombeDepartment of Surgery, University of Colorado, Aurora, CO.
R G GillDepartment of Surgery, University of Colorado, Aurora, CO.
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
NCATS NIH HHS UL1 TR001082NHLBI NIH HHS L30 HL129243NIAID NIH HHS L30 AI107942
6 · The paper itself

Abstract

Natural killer (NK) cells are key components of the innate immune system. In murine cardiac transplant models, donor-specific antibodies (DSA), in concert with NK cells, are sufficient to inflict chronic allograft vasculopathy independently of T and B cells. In this study, we aimed to determine the effector mechanism(s) required by NK cells to trigger chronic allograft vasculopathy during antibody-mediated rejection. Specifically, we tested the relative contribution of the proinflammatory cytokine interferon gamma (IFN-γ) versus the contact-dependent cytotoxic mediators of perforin and the CD95/CD95L (Fas/Fas ligand [FasL]) pathway for triggering these lesions. C3H/HeJ cardiac allografts were transplanted into immune-deficient C57BL/6 rag

Indexed as

Heart TransplantationAnimalsAntibodies, MonoclonalCytokinesFas Ligand Proteinfas ReceptorFemaleGraft RejectionHistocompatibility Antigens Class IInterferon-gammaKiller Cells, NaturalMaleMiceMice, Inbred C3HMice, Inbred C57BLPerforinAntibodies, MonoclonalCytokinesFas Ligand ProteinFas protein, mousefas ReceptorHistocompatibility Antigens Class IInterferon-gammaPerforinanimal models: murinebasic (laboratory) research/sciencecytokines/cytokine receptorsimmunobiologynatural killer (NK) cells/NK receptorsrejection: antibody-mediated (ABMR)rejection: chronic

Identifiers

PMID27163757
PMCPMC5083186
OpenAlexW2370779144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.